Favipiravir is an antiviral medication sold under the brand name Avigan among others and used to treat influenza in Japan. It is also being studied as a treatment for a number of other viral infections, including SARS-CoV-2. Chemically it is a pyrazinecarboxamide derivative, like the experimental antiviral drugs T-1105 and T-1106. It was developed and manufactured by Toyama Chemical, a subsidiary of Fujifilm, and was approved for medical use in Japan in 2014. In 2016 Fujifilm licensed it to Zhejiang Hisun Pharmaceutical Company, and it became a generic drug in 2019. The brand name Coronavir, under which this subject was queued, is one of the names the drug is sold under.
Facts
Classification
Approval Status ATC ClassJ: Antiinfectives for Systemic Use 2 First Approved / Isolated Year Mechanism of Action Sources
1. Favipiravir (Wikipedia)
LeadQuote, Lead
was approved for medical use in Japan in 2014
2. WHO Collaborating Centre for Drug Statistics Methodology, ATC/DDD Index: the WHO ATC/DDD Index entries named Favipiravir
WHO Collaborating Centre for Drug Statistics Methodology, ATC/DDD IndexATC/DDD Index entry; ATC class derived from cited code J05AX27 (main group J)Quote, ATC/DDD Index entry; ATC class derived from cited code J05AX27 (main group J)
J05AX27 favipiravir
3. ChEMBL: ChEMBL mechanism of action for Favipiravir (CHEMBL221722)
ChEMBLmechanism_of_actionQuote, mechanism_of_action
RNA-directed RNA polymerase inhibitor
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.